Lipoprotein(a) Blood Test: High Lp(a) and Your Risk
The lipoprotein(a) blood test measures an inherited, LDL-like particle that raises heart-disease and aortic-stenosis risk. Learn normal Lp(a) levels, high thresholds, and what to do.
Lipoprotein(a) — usually written Lp(a) — is a particle much like LDL (the "bad cholesterol") with one extra piece bolted on: a protein called apolipoprotein(a). Your Lp(a) level is almost entirely set by your genes and stays steady for life. A high Lp(a) is a cardiovascular risk factor in its own right, separate from your ordinary cholesterol — and it affects roughly one in five people. This guide explains normal Lp(a) levels, what a high result means, why the test is done once in a lifetime, and what to do about it without panic. Lp(a) is read alongside the rest of your lipid panel, next to LDL, apolipoprotein B, and total cholesterol.
Key takeaways
- Lp(a) is an LDL-like particle that also carries apolipoprotein(a); it is a causal, independent risk factor for cardiovascular disease.12
- Its level is about 80–90% genetically determined (some sources say > 90%), stable throughout life, and barely changed by diet, lifestyle, or statins.34
- High Lp(a) raises the risk of atherosclerosis (heart attack, stroke) and of aortic valve stenosis; it is elevated in about 1 in 5 people.13
- Common risk thresholds: ≥ 50 mg/dL or ≥ 125 nmol/L; nmol/L is the preferred unit, and you cannot convert between the two with a simple factor.12
- Measure it at least once in your lifetime (2022 ESC/EAS guidance); no fasting needed.15
- There is no specific approved treatment yet: the goal is to lower your overall risk (LDL, blood pressure, smoking). A high Lp(a) is not a life sentence.16
What is lipoprotein(a)?
Lipoprotein(a) is a cholesterol-carrying particle very similar to LDL: it has the same cholesterol-rich core and the same structural protein, apolipoprotein B (apoB). What sets it apart is an extra protein attached to it — apolipoprotein(a), or apo(a) — which gives Lp(a) both its name and its unique behavior.27
That apo(a) makes Lp(a) pro-inflammatory and prone to driving plaque buildup and calcification in arteries and on the aortic valve. Unlike LDL, whose level depends heavily on diet and medication, your Lp(a) concentration is set by a single gene (LPA): it is about 80–90% inherited, established in childhood, and essentially fixed for the rest of your life.43
Lp(a) is not LDL. Don't confuse Lp(a) with LDL cholesterol. LDL responds to diet and statins; Lp(a) does not. They are two distinct markers on the same lipid panel, and they add together when estimating your risk.
Why the test is done
Because a high Lp(a) is a hidden cardiovascular risk factor. You can have a perfectly normal total cholesterol and LDL and a high Lp(a) that, on its own, raises the risk of heart attack, stroke, and aortic valve stenosis. Large genetic and population studies show a link that is causal, continuous, and independent of other risk factors: the higher the Lp(a), the higher the risk.13
Major guidelines (ESC/EAS, 2022; and U.S. bodies including the NHLBI and the AHA/ACC) advise measuring Lp(a) at least once in adulthood. One measurement is usually enough, because the level doesn't change. It is especially useful when there is:158
- a family history of early heart attack or stroke;
- cardiovascular disease appearing without obvious risk factors;
- familial hypercholesterolemia or a known high Lp(a) in the family (cascade screening);
- a need to refine risk estimation and decide how aggressively to control other factors.
Knowing your Lp(a) can justify tighter control of LDL, blood pressure, and smoking — and can alert your relatives.
Do you need to fast?
No. Contrary to a common belief, the Lp(a) blood test does not require fasting: its concentration barely changes with meals because it is genetically fixed, so you can be drawn at any time of day. If Lp(a) is ordered together with the rest of your lipid panel (triglycerides, LDL), your clinician may still ask you to fast for those other measurements — follow the instructions on your order (see Do you need to fast before a blood test?).19
Normal ranges
Here are indicative adult reference points. Lp(a) is reported in mg/dL (mass) or nmol/L (particle number), and the preferred unit today is nmol/L, which is more reliable. Crucially, you cannot move from one unit to the other with a simple conversion factor, because they measure different things — so thresholds are given separately.12
| Interpretation | Lp(a) in mg/dL | Lp(a) in nmol/L |
|---|---|---|
| Desirable (low risk) | < 30 mg/dL | < 75 nmol/L |
| Intermediate (grey zone) | 30 – 50 mg/dL | 75 – 125 nmol/L |
| High (increased risk) | ≥ 50 mg/dL | ≥ 125 nmol/L |
Note: these thresholds are indicative and vary by lab and assay. Risk rises gradually with the level, without a sharp cutoff. Only your clinician can interpret the number in your context (family history, other risk factors).16
Understanding your results
High Lp(a): what it means
A high Lp(a) (≥ 50 mg/dL or ≥ 125 nmol/L) flags extra cardiovascular risk that adds to your other risk factors. Specifically, it is linked to:132
- greater risk of atherosclerosis: heart attack, coronary artery disease, peripheral artery disease, ischemic stroke;
- greater risk of aortic valve stenosis, driven by calcification of the valve — a well-established link that is specific to Lp(a);
- residual risk that persists even when LDL is well controlled on statins.
High Lp(a) is common: about 20–25% of people exceed 50 mg/dL. So it is neither rare nor a foregone conclusion — it's information to fold into your overall risk picture.23
Does a high Lp(a) mean immediate danger? No. It is a statistical risk factor, not a diagnosis. Many people with high Lp(a) never have a cardiac event. The point isn't to panic — it's to tighten everything else you can control: LDL, blood pressure, smoking, diabetes, and physical activity. That's where you have leverage.16
Lp(a) and cancer? Lp(a) is not a cancer marker and not a tumor marker. It speaks to your heart and arteries, not to a tumor.
Low Lp(a)
A low Lp(a) is reassuring here: it carries no risk and needs no treatment. Most people naturally have a low Lp(a) simply because their genetics produce little of it. There is nothing to "fix."
The Lp(a) – LDL – apoB trio
Lp(a) is never read alone. It sits alongside LDL and apolipoprotein B, which count total atherogenic particles. A high Lp(a) with a high LDL compounds the risk and calls for even tighter LDL control. Conversely, an isolated high Lp(a) (with a low LDL) explains extra risk that would otherwise look "unexplained." That cross-reading is what guides your clinician.71
What affects your Lp(a)
The dominant driver of Lp(a) is genetics (the LPA gene), which is why the level is stable and largely immune to lifestyle. Neither diet, nor exercise, nor statins meaningfully lower it — statins may even nudge it slightly upward. A few situations shift it modestly: Lp(a) averages about 17% higher in women after menopause than in men, and it can rise transiently with inflammation or kidney disease. Ancestry also affects average levels (higher in people of African descent). In short, your Lp(a) is mostly an inheritance, not a reflection of your habits.34
Recent research
According to recent PubMed-indexed publications:
- Specific treatments are finally on the horizon. With no drug able to lower Lp(a) until now, several targeted molecules in development reduce it by 65–98%. Three stand out: pelacarsen (an antisense oligonucleotide, ASO) and olpasiran (a small interfering RNA, siRNA), both injectable, plus muvalaplin, an oral inhibitor of Lp(a) formation.37
- Pelacarsen. In a phase 2 trial, pelacarsen lowered Lp(a) by up to about 80% in cardiac patients.10 It is now in a large phase 3 cardiovascular-outcomes trial, Lp(a)HORIZON, in more than 8,000 patients.11
- Olpasiran. In the phase 2 OCEAN(a)-DOSE trial, olpasiran reduced Lp(a) by roughly 95–100%.12 Its phase 3 outcomes trial (OCEAN(a)-Outcomes) is underway.13
- Muvalaplin. The first oral (pill) inhibitor, muvalaplin cut Lp(a) by up to 63–65% in phase 1 by blocking assembly of the particle.14
A crucial caveat: these drugs lower the number, but we don't yet know whether that reduces heart attacks and strokes — which is exactly what the phase 3 trials must prove. None is available in routine practice today. This information does not replace your physician's advice and does not authorize self-medication.
Get your Lp(a) interpreted by AI DiagMe
An Lp(a) level is never read alone: its meaning depends on your LDL, your apolipoprotein B, your total cholesterol, your family history, and your other risk factors. That cross-reading is what gives the result its real value.
👉 AI DiagMe interprets your lab results — blood, urine, or stool — in plain language, taking your whole profile into account. An informational service that does not provide a diagnosis and complements, never replaces, your physician.
Frequently asked questions
What is a lipoprotein(a) blood test?
What is a normal Lp(a) level?
What does a high Lp(a) mean?
How do you lower Lp(a)?
Do I need to fast for an Lp(a) test?
How often should Lp(a) be tested?
Is high Lp(a) inherited?
Is Lp(a) the same as cholesterol or LDL?
Does high Lp(a) mean cancer?
Bottom line
Lipoprotein(a) is an LDL-like particle that also carries apolipoprotein(a), with a level written into your genes (about 80–90%) and stable for life. It is a causal, independent cardiovascular risk factor, tied to both atherosclerosis and aortic valve stenosis, and elevated in about one in five people. Keep the thresholds in mind (≥ 50 mg/dL or ≥ 125 nmol/L, two units that don't interconvert, and lab-dependent), remember it's measured once in a lifetime with no fasting, and know that there's no specific treatment yet — the job is to lower your overall risk. A high Lp(a) is not a life sentence — it's a signal to tighten everything else. No value is read alone; it's your whole set of markers and your context that counts, which is what AI DiagMe provides, alongside your physician.
Sources
Official U.S. sources and peer-reviewed publications (PubMed, ClinicalTrials.gov) used for this guide:
Footnotes
-
Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society (EAS) consensus statement. Eur Heart J, 2022. PubMed · DOI ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13
-
Duarte Lau F, Giugliano RP. Lipoprotein(a) and Its Significance in Cardiovascular Disease: A Review. JAMA Cardiol, 2022. PubMed · DOI ↩ ↩2 ↩3 ↩4 ↩5 ↩6
-
Nordestgaard BG, Langsted A. Lipoprotein(a) and cardiovascular disease. Lancet, 2024. PubMed · DOI ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8
-
Tsioulos G, Kounatidis D, Vallianou NG, et al. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand? Int J Mol Sci, 2024. PubMed · DOI ↩ ↩2 ↩3
-
National Heart, Lung, and Blood Institute (NHLBI, NIH) — Blood Cholesterol / lipoprotein(a) and cardiovascular risk. nhlbi.nih.gov ↩ ↩2
-
Cleveland Clinic — Lipoprotein (a): What It Is, Test & Levels. my.clevelandclinic.org ↩ ↩2 ↩3
-
Tasdighi E, Adhikari R, Almaadawy O, et al. LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics. Annu Rev Pharmacol Toxicol, 2023. PubMed · DOI ↩ ↩2 ↩3
-
American Heart Association / American College of Cardiology (AHA/ACC) — Lipoprotein(a) and cardiovascular risk (scientific guidance). heart.org ↩
-
Testing.com — Lipoprotein (a) Test. testing.com ↩
-
Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease (pelacarsen, phase 2 trial). N Engl J Med, 2020. PubMed · DOI ↩
-
ClinicalTrials.gov — Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease (Lp(a)HORIZON). Identifier NCT04023552. clinicaltrials.gov ↩
-
O'Donoghue ML, Rosenson RS, Gencer B, et al. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease (olpasiran, OCEAN(a)-DOSE trial). N Engl J Med, 2022. PubMed · DOI ↩
-
ClinicalTrials.gov — Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) (OCEAN(a)-Outcomes). Identifier NCT05581303. clinicaltrials.gov ↩
-
Nicholls SJ, Nissen SE, Fleming C, et al. Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial. JAMA, 2023. PubMed · DOI ↩